Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 1 4Phase 3 2Phase 1/2 2

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Hereditary Sensory and Autonomic Neuropathies 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 35Carboplatin 24Specimen Handling 20Cyclophosphamide 19Magnetic Resonance Spectroscopy 18fludarabine 15Dexamethasone 15Nivolumab 14Gemcitabine 14Bevacizumab 14Biopsy 12atezolizumab 11Temozolomide 11Paclitaxel 10Docetaxel 10Cisplatin 10venetoclax 9Rituximab 9Pemetrexed 9Ipilimumab 9Prednisone 8Lenalidomide 8Fluorouracil 8blinatumomab 7Vincristine 7Radiotherapy 7Oxaliplatin 7Capecitabine 7olaparib 6lenvatinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × cemiplimab × 30 days × Clear all
NCT05882734 2026-05-28

Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

EMD Serono

Phase 1/2 Active not recruiting
61 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Hereditary Sensory and Autonomic Neuropathies

NCT07594106 2026-05-18

REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

Regeneron Pharmaceuticals

Phase 1/2 Not yet recruiting
265 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡